FORESEE PHARMACEUTICALS CO., LTD.

 

Area: Pharmaceutical and Medical Devices

Booth No: L226

Website: https://www.foreseepharma.com/en-us

 

Exhibitor Profile

 

Foresee Pharmaceuticals Co., Ltd. is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO).
a. CAMCEVI (FP-001): for prostate cancer/CPP, CAMCEVI 42 mg, is now approved in the U.S., Canada, and EU, and launched in the U.S. in April, 2022.
b. FP-025: an MMP-12 inhibitor, for asthma/COPD. The primary endpoint data of FP-025 in allergic asthma Phase 2a trial was announced with positive outcome.
c. FP-045: a ALDH2 activator, for Fanconi Anemia/Group 3 PH.

 

Brands

 

Foresee Pharmaceuticals Co., Ltd.

 

 

 

back